Table 1 Population and tumor characteristics
Age (years) | 55 (48–65) |
BMI (kg/m2) | 25 (22–29) |
Tobacco smoke | 12.5% (12/96) |
Family history | 42.22% (19/45) |
EP use | 31.82% (7/22) |
Post-menopausal status | 71.32% (97/136) |
Definitive breast surgery | |
Conservative | 31.62% (43/136) |
Mastectomy | 68.38% (93/136) |
Axilla surgery: definitive CALND | 69.12% (94/136) |
Non-surgical therapy | |
Neoadiuvant chemoterapy | 8.82% (12/136) |
Radiotherapy | 56.62% (77/136) |
vAdiuvant chemoterapy | 99.26% (135/136) |
Anti-hormonal therapy | 74.26% (101/136) |
Histology | |
Invasive ductal carcinoma | 80.88% (110/136) |
Invasive lobular carcinoma | 11.03% (15/136) |
Invasive ductal and lobular carcinoma | 6.62% (9/136) |
Other invasive cancers | 1.47% (2/136) |
Molecular types | |
Luminal A | 18.38% (25/136) |
Luminal B | 28.68% (39/136) |
Luminal HER2 | 8.09% (11/136) |
HER2 enriched | 11.03% (15/136) |
Basal-like | 13.97% (19/136) |
Not described | 19.85% (27/136) |
Other tumor caracteristics | |
Mib-1/Ki-67 (median percentage) | 30 (10–70) |
Mib-1/Ki-67 (> 20%) | 55.77% (58/104) |
Comedo-like nescrosis | 13.24% (18/136) |
Multifacality/multicentricity | 24.26% (33/136) |
Extended in situ component | 21.32% (29/136) |
Perivascular invasion | 40.44% (55/136) |
Lymph node characteristics | |
Micro-metastatic lymph nodes | 5.88% (8/136) |
Extracapsular invasion | 25.74% (35/136) |
Axilla lymph node bunching | 7.35% (10/136) |